{Reference Type}: Journal Article
{Title}: Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
{Author}: McIntyre RS;Wong S;Kwan ATH;Rhee TG;Teopiz KM;Ho R;Cao B;Mansur RB;Rosenblat JD;Le GH;
{Journal}: Expert Opin Drug Saf
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 3
{Factor}: 4.011
{DOI}: 10.1080/14740338.2024.2361300
{Abstract}: <B>UNASSIGNED: </B>Package inserts for the FDA-approved dual orexin receptor antagonists (DORAs) suvorexant, lemborexant and daridorexant state that suicide risk should be monitored. It remains unknown whether suicidality is attributed to DORAs. We aim to evaluate suicidality associated with DORAs reported to the FDA Adverse Event Reporting System (FAERS).<BR><B>UNASSIGNED: </B>The reporting odds ratio (ROR) was determined with trazodone as the control. Significant disproportionate reporting was determined when 95% confidence intervals (CIs) did not encompass 1.0. We used information components (ICs) to calculate the lower limit of the 95% CI (IC025). IC was significantly increased when the IC025 ≥0.<BR><B>UNASSIGNED: </B>Suvorexant (0.025 ROR), lemborexant (0.019 ROR) and daridorexant (0.002 ROR) were significantly associated with lower odds of reported completed suicides compared to trazodone (p < 0.05). There was no significantly increased RORs for the DORAs regarding suicidal ideation, depression suicidal, suicidal behavior and suicide attempts. Nonsignificant associations between all parameters of suicidality were observed for each DORA using IC025.<BR><B>UNASSIGNED: </B>We did not find a significant association between any parameter of suicidality captured in the FAERS for each DORA. All persons treated for insomnia pharmacologically/non-pharmacologically should be evaluated for emergence/worsening of any suicidality aspect.